The global women’s health specialist Hologic, Inc. has officially transitioned to a private company following the completion of its acquisition by funds managed by Blackstone and TPG. The deal provides stockholders with up to $79 per share. Significant minority investments from an affiliate of GIC and a subsidiary of the Abu Dhabi Investment Authority (ADIA) supported the transaction. As the acquisition concluded, Hologic announced that Joe Almeida has been appointed as the new Chief Executive Officer with immediate effect.
Almeida arrives at Hologic with a high profile in the medical technology sector. He previously served as the Chairman and CEO of Baxter International until early 2025. His career also includes leading Covidien plc through its major acquisition by Medtronic. Almeida succeeds Stephen MacMillan, who retired recently after leading Hologic for more than 12 years. The new chief executive expressed his enthusiasm for the role, noting that the backing of Blackstone and TPG provides the resources needed to drive innovation in healthcare.
The financial terms of the deal were first shared in October 2025 and received stockholder approval in February 2026. Shareholders are set to receive $76 per share in cash. An additional $3 per share is available through a non-tradable contingent value right (CVR). This extra payment depends on the Breast Health division meeting specific revenue targets during the 2026 and 2027 fiscal years. Following the deal, Hologic has been delisted from the Nasdaq Stock Market.
Ram Jagannath, Senior Managing Director and Global Head of Healthcare at Blackstone said, “Hologic has established itself as a global leader in advancing women’s health, with a proven track record of delivering life-changing medical technologies. We are thrilled to partner with Joe Almeida — an exceptional medical technology leader — alongside Hologic’s talented team and TPG to drive the company’s next phase of growth and innovation.”
Alex Albert, Partner at TPG and Co-Head of Healthcare for TPG Capital, added: “Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide. Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. Under Joe’s experienced and proven leadership, we are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.”
